Physician profile
Jonathan S Avula
NPI 1407142110
$1,167.59
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $717 · 2020: $301 · 2021: $48.20 · 2022: $31.97 · 2023: $69.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $69.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $69.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $265.55 | 2019-2023 | Trelegy Ellipta |
| Novo Nordisk INC | $214.14 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $166.86 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $108.85 | 2019-2023 | Fasenra, Farxiga |
| Lilly USA, LLC | $49.93 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.56 | 2019 | |
| Janssen Biotech, INC. | $45.95 | 2019-2020 | |
| Amgen INC. | $44.57 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $37.90 | 2019 | |
| Melinta Therapeutics, LLC | $30.91 | 2019 | |
| Novartis Pharmaceuticals Corporation | $25.24 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $23.78 | 2019-2020 | |
| Abbott Laboratories | $22.16 | 2023 | Freestyle Libre 3 |
| Viiv Healthcare Company | $21.86 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.72 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $16.00 | 2019 | |
| Pfizer INC. | $14.57 | 2020 | |
| Supernus Pharmaceuticals, INC. | $14.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Avula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.